Sorrento Therapeutics, Inc.
SRNE · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 18.8% | 32.3% | 27.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 46.8% | 75.4% | 75.1% | 61.1% |
| EBITDA | -$1 | -$0 | -$0 | -$0 |
| % Margin | -859.2% | -824.1% | -689.5% | -981.1% |
| Net Income | -$1 | -$0 | -$0 | -$0 |
| % Margin | -911.6% | -810.9% | -746.4% | -1,142.5% |
| EPS Diluted | -1.37 | -1.46 | -1.3 | -2.56 |
| % Growth | 6.2% | -12.3% | 49.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |